NCT03164109View on ClinicalTrials.gov

A Phase 1, Randomized, Placebo-and Positive-Controlled Crossover Study to Determine the Effect of Single-Dose GC4419 on QTc Interval in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 18, 2017

Primary Completion Date

October 13, 2017

Study Completion Date

October 13, 2017

Conditions
Healthy VolunteersHealthy
Interventions
DRUG

GC4419 IV

50mg infused IV over 15 minutes

DRUG

Placebo

Infused IV over 15 minutes

DRUG

Oral moxifloxacin

400 mg tablet orally with 250 mL room temperature water

Trial Locations (1)

3004

Nucleus Network Limited, Melbourne

Sponsors

Collaborators (1)

Syneos Health
All Listed Sponsors
collaborator

Syneos Health

OTHER

lead

Galera Therapeutics, Inc.

INDUSTRY